Table 2.

Univariate analysis of nonrelapse mortality in the cohort of patients analyzed

Number of patientsEventsCumulative incidence95% CIPHR*95% CIP
All patients 343 49 15% 11-19     
Sex         
 Male 210 25 12% 8-17 .116    
 Female 133 24 18% 13-27  1.57 0.90-2.74 .116 
Age at HSCT, y         
 <9.5 172 15 9% 6-15 .003    
 ≥9.5 171 34 20% 15-27  2.42 1.32-4.45 .004 
 <6 94 10 11% 6-20 .013    
 6-9.5 78 5 6% 3-15  0.59 0.20-1.72 .334 
 9.5-13 80 13 16% 10-27  1.59 0.69-3.65 .274 
 ≥13 91 21 24% 16-34  2.30 1.09-4.87 .029 
 <13 252 28 13% 8-16 .006    
 ≥13 91 21 24% 16-34  2.95 1.25-3.84 .006 
Diagnosis         
 ALL 237 37 16% 12-21 .281    
 AML 106 12 12% 7-20  0.79 0.37-1.34 .280 
ALL phenotype         
 B-cell precursor 191 29 16% 11-22     
 T-cell precursor 47 8 17% 9-32 .744 1.15 0.52-2.53 .732 
Disease phase at HSCT         
 Only ALL patients         
  CR1† 93 16 18% 11-28 .850    
  CR2 S1-S2† 85 11 13% 8-23  0.72 0.34-1.56 .405 
  CR2 S3-S4‡ 49 8 16% 9-31  0.93 0.40-2.17 .865 
  Other CR‡ 11 2 18% 5-64  1.98 0.24-4.83 .920 
 Only AML patients         
  CR1† 82 8 10% 5-19 .531    
  CR2† 22 4 18% 8-45  1.94 0.59-6.35 .273 
Prognosis†,‡         
 Good prognosis† 282 39 14% 11-19 .581    
 Poor prognosis‡ 61 10 16% 9-29  1.21 0.60-2.44 .583 
MRD, all patients         
 <1 × 10−3 143 16 11% 7-18 .855    
 ≥1 × 10−3 20 2 10% 3-37  0.87 0.20-3.73 .855 
 Neg 119 14 12% 7-19 .842    
 Pos <1 × 10−3 24 2 8% 2-31  0.66 0.16-2.80 .578 
 Pos ≥1 × 10−3 20 2 10% 3-37  0.82 0.19-3.55 .792 
MRD, only patients with ALL         
 <1 × 10−3 121 15 12% 8-20 .743    
 ≥1 × 10−3 11 1 9% 1-59  0.72 0.10-5.33 .744 
 Neg 98 13 13% 8-22 .756    
 Pos <1 × 10−3 23 2 9% 2-33  0.61 0.14-2.59 .503 
 Pos ≥1 × 10−3 11 1 9% 1-59  0.66 0.09-4.99 .678 
MRD, only patients with AML         
 <1 × 10−3 22 1 5% 1-31 .524    
 ≥1 × 10−3 9 1 11% 2-71  2.39 0.16-35.82 .529 
 Neg 21 1 5% 1-32 .802    
 Pos ≥1 × 10−3 9 1 11% 2-71  2.28 0.15-34.09  
Donor         
 MUD 245 40 17% 13-22 .085    
 Haploidentical 98 9 9% 5-17  0.54 0.26-1.11 .092 
HLA compatibility         
 MUD 127 8 6% 3-12 <.001    
 MMUD 118 32 28% 21-37  4.76 2.19-10-36 <.001 
 Haploidentical 98 9 9% 5-17  1.46 0.56-3.79 .435 
Stem cell source         
 BM 187 30 16% 12-23 .267    
 PBSC 156 19 12% 8-19  0.72 0.41-1.28 .268 
Conditioning regimen         
 TBI-based 204 31 16% 11-21 .827    
 Busulfan-based 115 16 14% 9-22  0.92 0.50-1.67 .774 
 Treosulfan-based 21 2 10% 3-36  0.64 0.15-2.79 .553 
Conditioning regimen, ALL patients         
 TBI-based 189 29 16% 11-22 .904    
 Busulfan-based 34 6 18% 9-36  0.21 0.49-2.99 .673 
 Treosulfan-based 12 2 17% 5-59  0.16 0.25-5.19 .846 
Conditioning regimen, AML patients         
 TBI-based 15 2 13% 4-48 .733    
 Busulfan-based 81 10 13% 7-23  0.93 0.21-4.24  
 Treosulfan-based 9 0 0% —  0.00 — <.001 
Number of patientsEventsCumulative incidence95% CIPHR*95% CIP
All patients 343 49 15% 11-19     
Sex         
 Male 210 25 12% 8-17 .116    
 Female 133 24 18% 13-27  1.57 0.90-2.74 .116 
Age at HSCT, y         
 <9.5 172 15 9% 6-15 .003    
 ≥9.5 171 34 20% 15-27  2.42 1.32-4.45 .004 
 <6 94 10 11% 6-20 .013    
 6-9.5 78 5 6% 3-15  0.59 0.20-1.72 .334 
 9.5-13 80 13 16% 10-27  1.59 0.69-3.65 .274 
 ≥13 91 21 24% 16-34  2.30 1.09-4.87 .029 
 <13 252 28 13% 8-16 .006    
 ≥13 91 21 24% 16-34  2.95 1.25-3.84 .006 
Diagnosis         
 ALL 237 37 16% 12-21 .281    
 AML 106 12 12% 7-20  0.79 0.37-1.34 .280 
ALL phenotype         
 B-cell precursor 191 29 16% 11-22     
 T-cell precursor 47 8 17% 9-32 .744 1.15 0.52-2.53 .732 
Disease phase at HSCT         
 Only ALL patients         
  CR1† 93 16 18% 11-28 .850    
  CR2 S1-S2† 85 11 13% 8-23  0.72 0.34-1.56 .405 
  CR2 S3-S4‡ 49 8 16% 9-31  0.93 0.40-2.17 .865 
  Other CR‡ 11 2 18% 5-64  1.98 0.24-4.83 .920 
 Only AML patients         
  CR1† 82 8 10% 5-19 .531    
  CR2† 22 4 18% 8-45  1.94 0.59-6.35 .273 
Prognosis†,‡         
 Good prognosis† 282 39 14% 11-19 .581    
 Poor prognosis‡ 61 10 16% 9-29  1.21 0.60-2.44 .583 
MRD, all patients         
 <1 × 10−3 143 16 11% 7-18 .855    
 ≥1 × 10−3 20 2 10% 3-37  0.87 0.20-3.73 .855 
 Neg 119 14 12% 7-19 .842    
 Pos <1 × 10−3 24 2 8% 2-31  0.66 0.16-2.80 .578 
 Pos ≥1 × 10−3 20 2 10% 3-37  0.82 0.19-3.55 .792 
MRD, only patients with ALL         
 <1 × 10−3 121 15 12% 8-20 .743    
 ≥1 × 10−3 11 1 9% 1-59  0.72 0.10-5.33 .744 
 Neg 98 13 13% 8-22 .756    
 Pos <1 × 10−3 23 2 9% 2-33  0.61 0.14-2.59 .503 
 Pos ≥1 × 10−3 11 1 9% 1-59  0.66 0.09-4.99 .678 
MRD, only patients with AML         
 <1 × 10−3 22 1 5% 1-31 .524    
 ≥1 × 10−3 9 1 11% 2-71  2.39 0.16-35.82 .529 
 Neg 21 1 5% 1-32 .802    
 Pos ≥1 × 10−3 9 1 11% 2-71  2.28 0.15-34.09  
Donor         
 MUD 245 40 17% 13-22 .085    
 Haploidentical 98 9 9% 5-17  0.54 0.26-1.11 .092 
HLA compatibility         
 MUD 127 8 6% 3-12 <.001    
 MMUD 118 32 28% 21-37  4.76 2.19-10-36 <.001 
 Haploidentical 98 9 9% 5-17  1.46 0.56-3.79 .435 
Stem cell source         
 BM 187 30 16% 12-23 .267    
 PBSC 156 19 12% 8-19  0.72 0.41-1.28 .268 
Conditioning regimen         
 TBI-based 204 31 16% 11-21 .827    
 Busulfan-based 115 16 14% 9-22  0.92 0.50-1.67 .774 
 Treosulfan-based 21 2 10% 3-36  0.64 0.15-2.79 .553 
Conditioning regimen, ALL patients         
 TBI-based 189 29 16% 11-22 .904    
 Busulfan-based 34 6 18% 9-36  0.21 0.49-2.99 .673 
 Treosulfan-based 12 2 17% 5-59  0.16 0.25-5.19 .846 
Conditioning regimen, AML patients         
 TBI-based 15 2 13% 4-48 .733    
 Busulfan-based 81 10 13% 7-23  0.93 0.21-4.24  
 Treosulfan-based 9 0 0% —  0.00 — <.001 

Subgroups including fewer than 5 patients were not shown in the table.

*

The Cox regression model was used to estimate the HR, and the first subgroup of patients of each independent variable was used as reference value.

†

The good prognosis group included patients affected by ALL in first CR, ALL in second CR after a relapse belonging to the S1-S2 risk groups and patients with AML in first CR.

‡

The poor prognosis group included patients affected by ALL in second CR after a relapse belonging to the S3-S4 risk groups, ALL in third or subsequent CR, and patients with AML in second CR.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal